MUMBAI — Lupin is looking to a longtime pharmaceutical industry veteran to head its business development and global mergers and acquisitions functions. The company named Jim Loerop its chief corporate development officer Monday, charging him with integrating its business development, licensing and M&A teams to drive its business strategy.
Loerop has been in the industry for 27 years, joining Lupin from Alexion Pharmaceuticals, where he was SVP global business development. Previously, he has worked for GlaxoSmithKline and its Stiefel, as well as KV Pharmaceutical and Curatek Pharmaceuticals. He started his career at Solvay Pharmaceuticals as a sales representative.
“We are delighted to welcome Jim at a crucial time as we accelerate our transition into complex generics and specialty brand segments,” Lupin CEO Vinita Gupta said. “Jim’s rich experience in both branded and generic business will be invaluable in helping us navigate our business towards new growth opportunities.”